Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 36 | 2020 | 813 | 1.980 |
Why?
|
| Oligodendroglioma | 15 | 2017 | 45 | 1.250 |
Why?
|
| Glioblastoma | 10 | 2020 | 281 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2020 | 1449 | 0.400 |
Why?
|
| Dacarbazine | 6 | 2017 | 100 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 2544 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 134 | 0.330 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2013 | 291 | 0.310 |
Why?
|
| Drug Therapy | 2 | 2009 | 68 | 0.300 |
Why?
|
| Evidence-Based Medicine | 8 | 2009 | 451 | 0.270 |
Why?
|
| Bevacizumab | 8 | 2020 | 256 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 6 | 2011 | 1396 | 0.250 |
Why?
|
| Astrocytoma | 4 | 2008 | 86 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2014 | 102 | 0.230 |
Why?
|
| Glioma | 2 | 2005 | 301 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 6 | 2009 | 1056 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2009 | 315 | 0.200 |
Why?
|
| Combined Modality Therapy | 12 | 2011 | 1723 | 0.200 |
Why?
|
| Salvage Therapy | 4 | 2010 | 235 | 0.190 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 2303 | 0.190 |
Why?
|
| Survival Rate | 13 | 2014 | 1948 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2017 | 96 | 0.170 |
Why?
|
| Parkinson Disease | 3 | 1990 | 175 | 0.170 |
Why?
|
| Encephalitis, California | 1 | 2000 | 1 | 0.170 |
Why?
|
| La Crosse virus | 1 | 2000 | 1 | 0.170 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2000 | 7 | 0.160 |
Why?
|
| Radiotherapy | 4 | 2016 | 320 | 0.160 |
Why?
|
| Carmustine | 3 | 2017 | 71 | 0.150 |
Why?
|
| Decanoic Acids | 1 | 2017 | 11 | 0.140 |
Why?
|
| Adult | 26 | 2020 | 27951 | 0.140 |
Why?
|
| Polyesters | 1 | 2017 | 44 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2013 | 1001 | 0.130 |
Why?
|
| Middle Aged | 26 | 2017 | 27610 | 0.130 |
Why?
|
| Humans | 43 | 2020 | 93611 | 0.120 |
Why?
|
| Levodopa | 2 | 1987 | 36 | 0.120 |
Why?
|
| Treatment Outcome | 15 | 2016 | 9104 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 86 | 0.120 |
Why?
|
| Procarbazine | 6 | 2011 | 26 | 0.120 |
Why?
|
| Lomustine | 6 | 2011 | 24 | 0.120 |
Why?
|
| Vincristine | 6 | 2011 | 99 | 0.110 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 1171 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2006 | 939 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 64 | 0.100 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 326 | 0.100 |
Why?
|
| Male | 26 | 2017 | 44575 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 214 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 167 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2013 | 299 | 0.100 |
Why?
|
| Aged | 17 | 2017 | 20462 | 0.100 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 3833 | 0.100 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 69 | 0.090 |
Why?
|
| Thiotepa | 4 | 2008 | 32 | 0.090 |
Why?
|
| Female | 25 | 2017 | 48773 | 0.090 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 180 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 239 | 0.090 |
Why?
|
| Movement Disorders | 1 | 1990 | 43 | 0.080 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 70 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 1990 | 80 | 0.080 |
Why?
|
| Radiosurgery | 2 | 2009 | 317 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2011 | 236 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2013 | 414 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2011 | 3479 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 289 | 0.070 |
Why?
|
| Steroids | 1 | 2009 | 168 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 163 | 0.070 |
Why?
|
| Meninges | 1 | 2008 | 14 | 0.070 |
Why?
|
| Young Adult | 7 | 2016 | 6936 | 0.070 |
Why?
|
| Prognosis | 6 | 2016 | 3912 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 62 | 0.070 |
Why?
|
| Neurosurgery | 1 | 2009 | 141 | 0.070 |
Why?
|
| MMPI | 1 | 1987 | 10 | 0.060 |
Why?
|
| Disease Progression | 5 | 2011 | 1532 | 0.060 |
Why?
|
| Seizures | 1 | 2009 | 311 | 0.060 |
Why?
|
| Hallucinations | 1 | 1987 | 29 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2007 | 83 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2008 | 1525 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 627 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 457 | 0.060 |
Why?
|
| Carbidopa | 1 | 1986 | 5 | 0.060 |
Why?
|
| Dystonia | 1 | 1986 | 31 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cranial Irradiation | 3 | 2009 | 40 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 876 | 0.050 |
Why?
|
| Adolescent | 7 | 2014 | 9609 | 0.050 |
Why?
|
| Stroke | 1 | 2013 | 1079 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 7068 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2017 | 4563 | 0.050 |
Why?
|
| DNA Modification Methylases | 2 | 2016 | 32 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2014 | 10184 | 0.050 |
Why?
|
| International Agencies | 2 | 2012 | 34 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 624 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2003 | 260 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 2017 | 359 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2000 | 41 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 61 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 137 | 0.040 |
Why?
|
| Iodine Radioisotopes | 2 | 1998 | 137 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 398 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 402 | 0.040 |
Why?
|
| Tenascin | 1 | 1998 | 9 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 181 | 0.030 |
Why?
|
| Karnofsky Performance Status | 3 | 2008 | 43 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2016 | 697 | 0.030 |
Why?
|
| Drug Implants | 1 | 2017 | 37 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 2018 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 61 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 512 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1546 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 192 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 1996 | 29 | 0.030 |
Why?
|
| Brain | 3 | 2008 | 2392 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 920 | 0.030 |
Why?
|
| Alleles | 1 | 1999 | 1139 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2009 | 1006 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2012 | 472 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 456 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 54 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 39 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 619 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 1103 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 401 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 994 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2015 | 506 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 988 | 0.020 |
Why?
|
| Etoposide | 2 | 2003 | 204 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2013 | 254 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 352 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1999 | 2591 | 0.020 |
Why?
|
| MEDLINE | 1 | 2009 | 8 | 0.020 |
Why?
|
| Metalloporphyrins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 83 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2009 | 97 | 0.020 |
Why?
|
| Biological Transport | 1 | 1990 | 404 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1661 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 543 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 505 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 84 | 0.020 |
Why?
|
| Camptothecin | 1 | 2009 | 196 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 61 | 0.020 |
Why?
|
| Cerebellopontine Angle | 1 | 2008 | 10 | 0.020 |
Why?
|
| Cerebrum | 1 | 2008 | 14 | 0.020 |
Why?
|
| Busulfan | 1 | 2008 | 42 | 0.020 |
Why?
|
| Time | 1 | 2008 | 80 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 829 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 298 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 572 | 0.010 |
Why?
|
| Meige Syndrome | 1 | 1986 | 1 | 0.010 |
Why?
|
| Pergolide | 1 | 1986 | 3 | 0.010 |
Why?
|
| Ergolines | 1 | 1986 | 8 | 0.010 |
Why?
|
| Bromocriptine | 1 | 1986 | 12 | 0.010 |
Why?
|
| Torticollis | 1 | 1986 | 12 | 0.010 |
Why?
|
| Data Collection | 1 | 2007 | 370 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 962 | 0.010 |
Why?
|
| Risk | 1 | 1987 | 657 | 0.010 |
Why?
|
| Psychometrics | 1 | 1987 | 337 | 0.010 |
Why?
|
| United States | 1 | 2017 | 7648 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 351 | 0.010 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1984 | 20 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 3061 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1984 | 40 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1984 | 97 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 1954 | 0.010 |
Why?
|
| Melphalan | 1 | 2003 | 98 | 0.010 |
Why?
|
| Methotrexate | 1 | 2003 | 225 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 132 | 0.010 |
Why?
|
| Cytarabine | 1 | 2003 | 216 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1741 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 738 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1984 | 275 | 0.010 |
Why?
|
| Cachexia | 1 | 2000 | 13 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 2000 | 37 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 293 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 281 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2000 | 172 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1998 | 21 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 104 | 0.010 |
Why?
|
| Immunoassay | 1 | 1998 | 99 | 0.010 |
Why?
|
| Cisplatin | 1 | 2000 | 568 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 166 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 367 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 29 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1996 | 53 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1996 | 225 | 0.010 |
Why?
|
| Biopsy | 1 | 1998 | 1177 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1998 | 761 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1996 | 3831 | 0.000 |
Why?
|
| Child | 1 | 1998 | 7358 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 304 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1984 | 173 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1984 | 309 | 0.000 |
Why?
|
| Perfusion | 1 | 1984 | 260 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 948 | 0.000 |
Why?
|
| Mice | 1 | 1996 | 12271 | 0.000 |
Why?
|
| Animals | 2 | 1996 | 28157 | 0.000 |
Why?
|
| Time Factors | 1 | 1990 | 5412 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 386 | 0.000 |
Why?
|
| Kinetics | 1 | 1984 | 1492 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1984 | 2850 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 4072 | 0.000 |
Why?
|